Abstract
This chapter introduces genomics and proteomics as the new generic tools for diagnosis of pituitary adenomas. The development of tumor-associated serum protein biomarkers over the past few decades has not been much effective for diagnosing primary neoplasia. There is a considerable pressure to discover new disease-related biomarkers. These markers are quantitative measures of biological effects that provide informative links between the mechanism of action and clinical effectiveness. They can provide new insights into a drug's mechanism of action, metabolism, efficacy, and safety, and into disease mechanisms and disease course. Protein biomarkers show a high potential of conversion into paraclinical diagnostic tests. Genomic analysis is one of the most intensively exploited “instrument” in biomarker discovery. Large-scale sequencing of candidate genes provides new biomarkers for tumor diagnosis and prognosis. Somatic DNA sequence analysis has expanded to genome-wide high-performance DNA sequencing leading to whole genome analysis of DNA sequence variations in tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
